Gilead Sciences Breaks Ground on $32 Billion AI-Enabled Biologics Development Center
核心洞察
Gilead Sciences has broken ground on a new 180,000 square foot Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City headquarters as part of a $32 billion U.S. investment through 2030.
The five-story facility will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharmaceutical industry.
The investment is projected to generate more than $43 billion in economic value nationwide and create over 3,000 direct and indirect high-quality jobs while strengthening Gilead's biologics (搜索) capabilities across virology (搜索), oncology (搜索), and inflammation (搜索).
Gilead Sciences has broken ground on its new Pharmaceutical Development and Manufacturing Technical Development Center (NTDC) at the company's Foster City headquarters, marking a significant milestone in the biotechnology company's $32 billion investment strategy to strengthen U.S. biopharmaceutical leadership through 2030.
The five-story, 180,000 square foot facility represents a cornerstone of Gilead's multi-year strategy to drive growth and scientific leadership across virology (搜索), oncology (搜索), and inflammation (搜索), with an increasing focus on biologics (搜索) capabilities. According to the company, this investment is projected to generate more than $43 billion in economic value nationwide while fueling high-quality jobs, research, and domestic manufacturing.
Advanced AI-Enabled Infrastructure
The NTDC will serve as a hub for innovation and collaboration across technical development and manufacturing teams, featuring flexible pilot lab space and advanced digital infrastructure designed to accelerate technology transfer. The facility will incorporate digitally enabled systems, autonomous robotics, and real-time digital monitoring, positioning it as one of the most AI-enabled centers in the biopharmaceutical industry.
"This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead's $32 billion investment commitment in the United States," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation."
Strengthening Biologics Capabilities
The new facility will strengthen Gilead's biologics (搜索) capacity and capabilities, which represents a central pillar of the company's growth strategy. The NTDC is designed to support the advancement of next-generation biologics across Gilead's pipeline, building on the company's broader U.S. efforts to expand research and manufacturing capabilities.
California Lieutenant Governor Eleni Kounalakis emphasized the broader economic impact, stating: "This new Technical Development Center is more than a milestone for Gilead; it's a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation."
Broader Foster City Expansion
The groundbreaking is part of a comprehensive expansion at Gilead's Foster City headquarters. In addition to the NTDC, the company is currently developing two other state-of-the-art facilities: a new research building designed to accelerate scientific discovery, already under construction, and a biologics (搜索) manufacturing facility that will expand domestic production capacity.
These current investments build on Gilead's strong history of U.S. investment, with more than $15 billion invested over the last decade. The company's broader U.S. efforts are expected to create more than 3,000 direct and indirect high-quality jobs while advancing equitable access to healthcare nationwide.
Economic Impact and Strategic Vision
Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead's role as a U.S.-based biopharmaceutical leader in improving human health globally. The comprehensive approach demonstrates the company's commitment to strengthening America's biopharmaceutical leadership while maintaining its position as a major contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for patients.